Abstract
We analyzed the effect of interferon α (IFN-α) and ribavirin (RBV) therapy on cell-associated human T-lymphotropic virus type 2 (HTLV-2) DNA in HIV-1-coinfected patients receiving antiretroviral therapy. Sixty-one patients under suppressive antiretroviral therapy were included: 37 with hepatitis C virus (HCV) infection, 15 with sustained virologic response (N = 10), relapse (N = 2), or with nonresponse (N = 3) after IFN-α/RBV treatment, and 9 with spontaneous HCV RNA clearance. Patients who were treated with IFN-α/RBV or had spontaneous HCV clearance had lower level of cell-associated HTLV-2 DNA (P = 0.022 and P = 0.040, respectively). Both IFN-alpha treatment and the ability to spontaneously clear HCV infection seem to reduce cell-associated HTLV-2 DNA in HIV-1-coinfected patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / therapeutic use*
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / therapeutic use
-
CD8-Positive T-Lymphocytes / immunology
-
DNA, Viral / isolation & purification*
-
Female
-
HIV Infections / complications*
-
HIV Infections / virology
-
HIV-1
-
Hepacivirus / classification
-
Hepacivirus / genetics
-
Hepatitis C / complications*
-
Hepatitis C / virology
-
Human T-lymphotropic virus 2 / genetics*
-
Humans
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / therapeutic use
-
Interleukin-6 / metabolism
-
Male
-
Middle Aged
-
RNA, Viral / immunology*
-
Ribavirin / administration & dosage
-
Ribavirin / therapeutic use
Substances
-
Anti-HIV Agents
-
Antiviral Agents
-
DNA, Viral
-
Interferon-alpha
-
Interleukin-6
-
RNA, Viral
-
Ribavirin